Skip to main content

Table 4 The results of Cox regression analysis

From: Establishment and validation of a prognosis nomogram for MIMIC-III patients with liver cirrhosis complicated with hepatic encephalopathy

 

Univariate cox model

Multivariable cox model

Variables

HR

95%CI

P value

HR

95%CI

P value

Age

1.013

1.000–1.025

0.053

1.022

1.006–1.037

0.006

Mean SpO2

0.946

0.910–0.982

0.004

   

Mean heart rate

1.008

1.000–1.016

0.044

1.013

1.003–1.023

0.010

MAP

0.965

0.952–0.978

 < 0.001

0.982

0.967–0.998

0.031

Mean respiratory rate

1.038

1.008–1.070

0.014

   

Mean temperature

0.583

0.465–0.731

 < 0.001

0.731

0.554–0.966

0.027

Cardiac arrhythmias

 No

Reference

     

 Yes

1.468

1.054–2.046

0.023

   

 SOFA

1.106

1.064–1.150

 < 0.001

1.057

0.998–1.119

0.059

 MELD

1.037

1.022–1.051

 < 0.001

   

 Lactate

1.090

1.033–1.141

0.001

   

 UrineOutput

1.000

1.000–1.000

 < 0.001

   

 Albumin

0.776

0.603–0.999

0.049

   

 Total bilirubin

1.022

1.010–1.035

 < 0.001

   

 Urea nitrogen

1.007

1.002–1.011

0.005

   

 Sodium

0.972

0.954–0.990

0.003

   

 Magnesium

1.491

1.132–1.964

0.004

   

 Chloride

0.969

0.953–0.986

 < 0.001

   

 Potassium

1.159

1.016–1.323

0.028

   

 INR

1.175

1.029–1.342

0.018

   

 RDW

1.100

1.039–1.163

 < 0.001

1.056

0.994–1.122

0.078

 WBC

1.031

1.013–1.050

 < 0.001

   

 ALP

1.001

1.000–1.002

0.058

   

 PT

1.018

1.000–1.036

0.048

   

 PTT

1.007

1.000–1.014

0.041

   

 PPI use

0.761

0.558–1.038

0.085

0.702

0.500–0.985

0.041

 Furosemide use

0.698

0.529–0.921

0.011

   

 Albumin use

2.004

1.509–2.662

 < 0.001

1.428

1.013–2.011

0.042

 PAD

1.652

1.244–2.193

 < 0.001

   
  1. HR hazard ratio, CI confidence interval, MAP Mean arterial pressure, ALP Alkaline phosphatase, INR International normalized ratio, PT Prothrombin time, PTT Partial thromboplastin time, RDW Red cell distribution width, WBC White blood cell count, PPI.use Proton pump inhibitors use, PAD Percutaneous abdominal drainage, SOFA Sequential organ failure assessment, MELD Model for end-stage liver disease